Association of post-cardioversion transcardiac concentration gradient of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) and inflammatory biomarkers to atrial fibrillation recurrence

Clinical Biochemistry

Volumn 46, Issue 12, 2013, Pages 1020-1025

  Deftereos, Spyridon ^a   Giannopoulos, Georgios ^a,b   Kossyvakis, Charalambos ^a   Raisakis, Konstantinos ^a   Angelidis, Christos ^a   Efremidis, Michalis ^c   Panagopoulou, Vasiliki ^a   Kaoukis, Andreas ^a   Theodorakis, Andreas ^d   Toli, Konstantina ^e   Zavitsanakis, Panagiotis ^d   Mantas, Ioannis ^e   Pyrgakis, Vlasios ^a   Stefanadis, Christodoulos ^f   Cleman, Michael W ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EVANGELISMOS HOSPITAL   (Greece)

^d General Hospital of Mesologgi   (Greece)

^e General Hospital of Chalkida   (Greece)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apoptosis; Atrial fibrillation; C reactive protein; Interleukin 6; Recurrence; STRAIL

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; CARDIOVERSION; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CORONARY ARTERY DISEASE; CORONARY SINUS; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SMOKING;

APOPTOSIS; ATRIAL FIBRILLATION; C-REACTIVE PROTEIN; INTERLEUKIN-6; RECURRENCE; STRAIL;

AGED; APOPTOSIS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RECURRENCE; SOLUBILITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84880514319     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.02.003     Document Type: Article

References (34)

1. Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001, 86:516-521.
2. Heidbüchel H. A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy?. Eur Heart J 2003, 24:2077-2078.
3. Aimé-Sempé C., Folliguet T., Rücker-Martin C., Krajewska M., Krajewska S., Heimburger M., et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999, 34:1577-1586.
4. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
5. Liabeuf S., Barreto D.V., Barreto F.C., Chasseraud M., Brazier M., Choukroun G., et al. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 2010, 25:2596-2602.
6. Daniels R.A., Turley H., Kimberley F.C., Liu X.S., Mongkolsapaya J., Ch'En P., et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005, 15:430-438.
7. Zauli G., Pandolfi A., Gonelli A., Di Pietro R., Guarnieri S., Ciabattoni G., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 2003, 92:732-740.
8. Secchiero P., Corallini F., di Iasio M.G., Gonelli A., Barbarotto E., Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 2005, 105:3413-3419.
9. Secchiero P., Candido R., Corallini F., Zacchigna S., Toffoli B., Rimondi E., et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006, 114:1522-1530.
10. Niessner A., Hohensinner P.J., Rychli K., Neuhold S., Zorn G., Richter B., et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009, 30:789-796.
11. Deftereos S., Giannopoulos G., Kossyvakis C., Kaoukis A., Raisakis K., Panagopoulou V., et al. Association of soluble tumour necrosis factor-related apoptosis-inducing ligand levels with coronary plaque burden and composition. Heart 2012, 98:214-218.
12. Trappe K., Thomas D., Bikou O., Kelemen K., Lugenbiel P., Voss F., et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J 2011, [E-pub ahead of print]. 10.1093/eurheartj/ehr269.
13. Osmancik P., Peroutka Z., Boudera P., Herman D., Stros P., Straka Z., et al. Decreased apoptosis following successful ablation of atrial fibrillation. Cardiology 2010, 116:302-307.
14. Henningsen K.M., Therkelsen S.K., Bruunsgaard H., Krabbe K.S., Pedersen B.K., Svendsen J.H. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest 2009, 69:425-432.
15. Leftheriotis D.I., Fountoulaki K.T., Flevari P.G., Parissis J.T., Panou F.K., Andreadou I.T., et al. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol 2009, 135:361-369.
16. Masson S., Aleksova A., Favero C., Staszewsky L., Bernardinangeli M., Belvito C., et al. Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. Heart 2010, 96:1909-1914.
17. Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man anatomic validation of the method. Circulation 1977, 55:613-618.
18. Hayashi M., Tsutamoto T., Wada A., Maeda K., Mabuchi N., Tsutsui T., et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001, 38:1375-1382.
19. Dilaveris P., Giannopoulos G., Synetos A., Stefanadis C. The role of renin angiotensin system blockade in the treatment of atrial fibrillation. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:387-403.
20. Watt V., Chamberlain J., Steiner T., Francis S., Crossman D. TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2011, 215:348-354.
21. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003, 107:2250-2256.
22. Chan J., Prado-Lourenco L., Khachigian L.M., Bennett M.R., Di Bartolo B.A., Kavurma M.M. TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res 2010, 106:1061-1071.
23. Secchiero P., Zerbinati C., Rimondi E., Corallini F., Milani D., Grill V., et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004, 61:1965-1974.
24. Harding P., Murray D.B. The contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failure. Life Sci 2011, 89:671-676.
25. Ueland T., Yndestad A., Øie E., Florholmen G., Halvorsen B., Frøland S.S., et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005, 111:2461-2468.
26. Cao H., Li Q., Li M., Od R., Wu Z., Zhou Q., et al. Osteoprotegerin/RANK/RANKL axis and atrial remodeling in mitral valvular patients with atrial fibrillation. Int J Cardiol 2011, [E-pub ahead of print]. 10.1016/j.ijcard.2011.11.09.
27. Moran C.S., McCann M., Karan M., Norman P., Ketheesan N., Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005, 111:3119-3125.
28. Schnabel R.B., Larson M.G., Jamamoto J.F., Kathiresan S., Rong J., Levy D., et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009, 104:92-96.
29. Corallini F., Celeghini C., Rimondi E., di Iasio M.G., Gonelli A., Secchiero P., et al. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. J Cell Physiol 2011, 226:2279-2286.
30. Malouf J.F., Kanagala R., Al Atawi F.O., Rosales A.G., Davison D.E., Murali N.S., et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005, 46:1284-1287.
31. Watanabe E., Arakawa T., Uchiyama T., Kodama I., Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006, 108:346-353.
32. Liu T., Li G., Li L., Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007, 49:1642-1648.
33. Cosgrave J., Foley J.B., Bahadur K., Bennett K., Crean P., Walsh M.J. Inflammatory markers are not associated with outcomes following elective external cardioversion. Int J Cardiol 2006, 110:373-377.
34. Dimberg L.Y., Anderson C.K., Camidge R., Behbakht K., Thorburn A., Ford H.L. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2012, [Epub ahead of print]. 10.1038/onc.2012.164.